Literature DB >> 18591634

Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women.

Jeanne M Marrazzo1, Katherine K Thomas, Tina L Fiedler, Kathleen Ringwood, David N Fredricks.   

Abstract

BACKGROUND: Bacterial vaginosis frequently persists after treatment. The role of newly defined bacterial vaginosis-associated bacteria (BVAB), which have a specificity for this condition of 97% or greater, has not been assessed.
OBJECTIVE: To define risks for bacterial vaginosis persistence, including pretreatment detection of specific vaginal bacteria, among women reporting sex with women.
DESIGN: Observational cohort study.
SETTING: University-based research clinic. PATIENTS: 335 women age 16 to 29 years reporting sex with at least 1 woman in the past year. Participants were recruited through advertisements and provider referral. INTERVENTION: Bacterial vaginosis was treated with intravaginal metronidazole gel (0.75%), 37.5 mg nightly for 5 nights. MEASUREMENTS: Species-specific 16S recombinant DNA polymerase chain reaction assays targeting 17 bacterial species were applied to vaginal fluid obtained at baseline. Test of cure by clinical criteria and Gram stain analysis and repeated polymerase chain reaction assays of vaginal fluid were performed 1 month after treatment, and interim behaviors were assessed by using computer-assisted self-interview.
RESULTS: Of 335 women, 24% of whom also reported sex with men within 3 months before enrollment, 131 (39%) had bacterial vaginosis. In the 120 (92%) women who returned for follow-up, the incidence of persistent bacterial vaginosis was 26% and was statistically significantly higher in women with baseline detection of 3 Clostridiales bacteria, designated as BVAB1 (risk ratio, 2.0 [95% CI, 1.1 to 4.0]), BVAB2 (risk ratio, 8.7 [CI, 2.5 to infinity]), or BVAB3 (risk ratio, 3.1 [CI, 1.7 to 5.8]); Peptoniphilus lacrimalis (risk ratio, 3.5 [CI, 1.6 to 15.5]); and Megasphaera phylotype 2 (risk ratio, 3.4 [CI, 1.4 to 5.5]). Persistence was lower with treatment adherence (risk ratio, 0.4 [0.2 to 0.9]). Detection of these bacteria at the test-of-cure visit was associated with persistence, whereas posttreatment sexual activity was not. LIMITATIONS: Findings may not be generalizable to women who have sex only with men, or to women whose bacterial vaginosis is treated with oral antibiotics. The study may be too small and may involve a population that is too highly selected to draw definitive conclusions about associations of persistent infection with posttreatment sexual behaviors.
CONCLUSION: Persistent bacterial vaginosis is associated with several bacteria in the Clostridiales order, Megasphaera phylotype 2, and P. lacrimalis, suggesting that vaginal microbiology at diagnosis may determine risk for antibiotic failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591634      PMCID: PMC2630802          DOI: 10.7326/0003-4819-149-1-200807010-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  36 in total

1.  The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy.

Authors:  C S Bradshaw; S N Tabrizi; C K Fairley; A N Morton; E Rudland; S M Garland
Journal:  J Infect Dis       Date:  2006-08-16       Impact factor: 5.226

2.  Plasmid analysis and antimicrobial susceptibilities of Peptostreptococcus species.

Authors:  L K Ng; J A Dillon
Journal:  FEMS Microbiol Lett       Date:  1989-10-01       Impact factor: 2.742

3.  Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial.

Authors:  Sixto Sanchez; Patricia J Garcia; Katherine K Thomas; Mary Catlin; King K Holmes
Journal:  Am J Obstet Gynecol       Date:  2004-12       Impact factor: 8.661

4.  Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis.

Authors:  Jack D Sobel; Daron Ferris; Jane Schwebke; Paul Nyirjesy; Harold C Wiesenfeld; Jeffrey Peipert; David Soper; Suzanne E Ohmit; Sharon L Hillier
Journal:  Am J Obstet Gynecol       Date:  2006-04-21       Impact factor: 8.661

5.  Antimicrobial susceptibility of comma-shaped bacteria isolated from the vagina.

Authors:  A Skarin; E Holst; P A Mårdh
Journal:  Scand J Infect Dis Suppl       Date:  1983

6.  Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis.

Authors:  C H Livengood; D E Soper; K L Sheehan; D E Fenner; M G Martens; A L Nelson; M Ismail; J M Thorp; M Lappin; B J Long; T Blackwelder; R L Sweet; S Sagov
Journal:  Sex Transm Dis       Date:  1999-03       Impact factor: 2.830

7.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.

Authors:  R P Nugent; M A Krohn; S L Hillier
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

8.  Curved anaerobic bacteria in bacterial (nonspecific) vaginosis and their response to antimicrobial therapy.

Authors:  C A Spiegel; D A Eschenbach; R Amsel; K K Holmes
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

9.  Bacterial vaginosis: efficacy and safety of intravaginal metronidazole treatment.

Authors:  C H Livengood; J A McGregor; D E Soper; E Newton; J L Thomason
Journal:  Am J Obstet Gynecol       Date:  1994-03       Impact factor: 8.661

10.  Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis.

Authors:  Michael J Ferris; Alicia Masztal; Kenneth E Aldridge; J Dennis Fortenberry; Paul L Fidel; David H Martin
Journal:  BMC Infect Dis       Date:  2004-02-13       Impact factor: 3.090

View more
  58 in total

1.  Clinical pearls in infectious diseases.

Authors:  Robert Orenstein; Scott C Litin
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

2.  Emerging Sexual Health Issues Among Women Who Have Sex with Women.

Authors:  Jeanne M Marrazzo; Linda M Gorgos
Journal:  Curr Infect Dis Rep       Date:  2012-02-02       Impact factor: 3.725

3.  Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR.

Authors:  David N Fredricks; Tina L Fiedler; Katherine K Thomas; Caroline M Mitchell; Jeanne M Marrazzo
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

4.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

5.  Molecular analysis of the relationship between specific vaginal bacteria and bacterial vaginosis metronidazole therapy failure.

Authors:  B Wang; B B Xiao; C G Shang; K Wang; R S Na; X X Nu; Q Liao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-10       Impact factor: 3.267

6.  Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study.

Authors:  Jeanne M Marrazzo; Katherine K Thomas; Tina L Fiedler; Kathleen Ringwood; David N Fredricks
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

7.  Characteristic male urine microbiomes associate with asymptomatic sexually transmitted infection.

Authors:  David E Nelson; Barbara Van Der Pol; Qunfeng Dong; Kashi V Revanna; Baochang Fan; Shraddha Easwaran; Erica Sodergren; George M Weinstock; Lixia Diao; J Dennis Fortenberry
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

Review 8.  Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation.

Authors:  Catriona S Bradshaw; Jack D Sobel
Journal:  J Infect Dis       Date:  2016-08-15       Impact factor: 5.226

9.  The human vaginal bacterial biota and bacterial vaginosis.

Authors:  Sujatha Srinivasan; David N Fredricks
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-02-16

10.  Community analysis of chronic wound bacteria using 16S rRNA gene-based pyrosequencing: impact of diabetes and antibiotics on chronic wound microbiota.

Authors:  Lance B Price; Cindy M Liu; Johan H Melendez; Yelena M Frankel; David Engelthaler; Maliha Aziz; Jolene Bowers; Rogan Rattray; Jacques Ravel; Chris Kingsley; Paul S Keim; Gerald S Lazarus; Jonathan M Zenilman
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.